[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cannabis-use-disorder-moderate\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cannabis-use-disorder-moderate":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100644478","phase-3-tirzepatide-in-the-treatment-of-cannabis-use-disorder-100644478",false,"NCT07671248","Tirzepatide in the Treatment of Cannabis Use Disorder","A 12-Week Phase 3 Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Tirzepatide-Assisted-Psychotherapy in Adults With Cannabis Use Disorder: A Proof-of-Concept Study","Inclusion Criteria:\n\n* Adults aged 18 and above\n* DSM-5 Cannabis Use Disorder diagnosis of at least moderate severity (4+ DSM-5 symptoms)\n* 4 or more days of cannabis use per week\n* Treatment seeking\n* A Body Mass Index (BMI) ≥ 22\n\nExclusion Criteria:\n\n* Meet DSM-5 criteria for Cluster A or B personality disorders and\u002For unstable current bipolar disorder, schizophrenia, or psychotic disorder\n* Comorbid severe DSM-5 Major Depressive Disorder\n* Present a serious suicide risk or who are likely to require psychiatric hospitalization during the course of the study, as determined by the study physician and Columbia Suicide Severity Rating Scale\n* Any other mental health condition deemed incompatible by the study team\n* Meet DSM-5 criteria for alcohol or substance use disorder for any substance other than cannabis or tobacco in the past 6 months\n* Positive urine drug screen for any substance except cannabis\n* Concurrent addiction-focused psychotherapy in the past 6 months\n* Unstable management of an existing mental health condition or anticipation of a change to the treatment over the next 3 months\n* A personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2\n* Current unstable medical condition\n* A lifetime diagnosis of Diabetes\n* Females who are pregnant\u002Fnursing, or individuals in reproductive age who do not consent to using birth control during the study\n* Concomitant treatment with: other GLP-1 agonists, Contrave, bupropion, naltrexone, acamprosate within the past year. No lifetime treatment with tirzepatide.\n* Significant literacy, visual, or hearing problems\n* Co-enrollment in a clinical drug trial","ALL","18 Years",{"count":19,"type":20},15,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","Cannabis is the most commonly used psychoactive substance in Canada. A sub-group of cannabis users develop Cannabis Use Disorder (CUD). CUD is a pattern of cannabis use that results in impairment in functioning, symptoms of tolerance, withdrawal, and distress. Several pharmacological and psychosocial interventions have been evaluated for their efficacy in treating CUD, however they lack high success rates. GLP-1RA's have shown promising results in reducing food and alcohol cravings and intake. Tirzepatide acts as both a GLP-1RA and a glucose-dependent insulinotropic polypeptide receptor agonist. Tirzepatide has been reported to reduce alcohol consumption, and therefore may have promising effects as a treatment for CUD. This study aims to evaluate the feasibility and tolerability of weekly injections of Tirzepatide combined with Motivational Enhancement Therapy in adults with CUD. This trial will be the first to examine the potential therapeutic effects of Tirzepatide in CUD.",[26,27],"Cannabis Use Disorder, Moderate","Cannabis Use Disorder, Severe",[29,30,31],"Cannabis Use Disorder","Motivational Enhancement Therapy","Tirzepatide","NOT_YET_RECRUITING","2026-06-29",{"date":35,"type":36},"2026-07-01","ACTUAL",{"date":38,"type":20},"2026-08-01",{"date":40,"type":20},"2028-07-31",{"name":42,"class":43},"McMaster University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":44},"100444199","phase-2-gabapentin-for-restoring-gabaglutamate-homeostasis-in-co-occurring-bipolar-and-cannabis-use-disorders-100444199","NCT05064319","Gabapentin for Restoring GABA\u002FGlutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders","Gabapentin for Restoring GABA\u002FGlutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders: A Randomized, Double-blind, Placebo-controlled, Parallel-group, MRI Study","Inclusion Criteria:\n\n1. Ages 18-65 years\n2. Meet DSM-5 criteria for moderate or severe cannabis use disorder (CUD; within the past 3 months), provide a positive urine cannabinoid screen at baseline, and identify cannabis as the primary substance of abuse\n3. Meet DSM-5 criteria for bipolar I or II disorder (BD) or Schizoaffective Disorder, Bipolar Type\n4. Able to provide informed consent and read, understand, and accurately complete assessment instruments\n5. Willing to commit to medication treatment and follow-up assessments\n6. Prescribed daily use of at least one mood stabilizing medication (i.e., lithium, divalproex sodium, lamotrigine, carbamazepine, 2nd generation antipsychotic)\n\nExclusion Criteria:\n\n1. A primary psychiatric diagnosis other than BD (e.g., Schizophrenia)\n2. Meet DSM-5 criteria for moderate or severe substance use disorder (other than cannabis or tobacco) within the past 60 days\n3. Any uncontrolled neurological condition (e.g., epilepsy) that could confound the results of the study\n4. Any history of brain injury with loss of consciousness greater than 5 minutes\n5. Any history of mental retardation, dementia, or recent electroconvulsive therapy (in the past 3 months)\n6. Any uncontrolled medical condition that may adversely affect the conduct of the study or jeopardize the safety of the participant\n7. Hepatocellular disease as indicated by plasma levels of liver transaminases (aspartate transaminase, alanine transaminase) greater than 3 times the normal range\n8. Renal insufficiency as indicated by plasma levels of creatinine greater than 2 times the normal range\n9. Concomitant use of medications that could interfere with glutamatergic\u002FGABAergic transmission (e.g., benzodiazepines, ceftriaxone, riluzole, memantine, ketamine, topiramate, vigabatrin), due to potential confounding effects\n10. Concomitant use of opioid medications, benzodiazepines, barbiturates, chloral hydrate, sodium oxybate, or any other medication deemed to be hazardous if taken with gabapentin\n11. Azelastine, orphenadrine, oxomemazine, paraldehyde, and thalidomide are generally contraindicated in patients taking gabapentin; as such, individuals taking these medications will be excluded\n12. Women of childbearing potential who are pregnant, lactating, or refuse adequate forms of contraception\n13. Current suicidal or homicidal risk\n14. Baseline scores greater than 35 on the Montgomery-Asberg Depression Rating Scale or greater than 25 on the Young Mania Rating Scale\n15. Has taken gabapentin in the last month or experienced adverse effects\u002Fallergic reaction (e.g., angioedema) from it at any time\n16. Significant claustrophobia and\u002For past negative experiences with MRI\n17. Presence of non-MRI safe materials in the body (e.g., ferrous metal implants, pacemaker)","65 Years",{"count":54,"type":20},68,[56],"PHASE2","This research study evaluates the effects of an FDA-approved medication Gabapentin in individuals with Bipolar Disorder who smoke marijuana. Participants in the study will will be assigned to take either Gabapentin or a matched placebo. Study medication will be taken for 17 days. There will be 5 study visits, with 2 MRI brain imaging scans completed. Questionnaires and clinical interview measures will be completed at study visits along with consistent assessment of potential side effects from study medication.",[59,60,61,62,63,64,26,27],"Bipolar Disorder","Cannabis Use","Schizoaffective Disorder, Bipolar Type","Bipolar I Disorder","Bipolar II Disorder","Cannabis Use Disorder, Mild","RECRUITING","2025-07-02",{"date":68,"type":36},"2025-07-08",{"date":70,"type":36},"2022-02-24",{"date":72,"type":20},"2026-06-30",{"name":74,"class":43},"Medical University of South Carolina",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":85,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":44},"100533393","phase-2-psilocybin-in-the-treatment-of-cannabis-use-disorder-a-proof-of-concept-study-100533393","NCT06225232","Psilocybin in the Treatment of Cannabis Use Disorder: A-Proof-of-Concept Study","An 8-week Phase 2 Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Psilocybin-assisted-psychotherapy in Adults With Cannabis Use Disorder: A Proof-of-Concept Study","PSI_CUD","Inclusion Criteria:\n\n1. Signed Informed Consent Form.\n2. Able to show documentation of identity.\n3. Fluent in speaking and reading English and able to complete rating scales and assessments.\n4. Between the ages of 18 to 65.\n5. At Screening, meet criteria for CUD diagnosis of at least moderate severity as per the MINI Plus\n6. Expressed a wish to reduce or stop cannabis use.\n7. Medically healthy based on physician review of CBC, electrolytes, liver function test, kidney function tests and ECG.\n8. Has a stable residence for the duration of the study.\n9. Agree to comply with the protocol requirements set out by the study.\n10. Consent to providing regular check-ins and follow-up regarding any medical conditions, procedures and adverse events.\n11. If of child-bearing potential, female participants must agree to use an adequate birth control method (IUD, injected or implanted hormonal methods, abstinence, vasectomy of the partner\u002Fpartners, or double barrier contraception i.e. condoms plus diaphragm, or diaphragm plus spermicide) for the duration of the study. Male participants should agree to using condoms with spermicide throughout the trial in addition to the use of an adequate contraceptive by their partner of childbearing potential.\n12. Following discharge from the dosing sessions, agree to have another individual accompany them home from the study site and stay with them overnight.\n\nExclusion Criteria:\n\n1. Meet DSM-5 criteria for lifetime history of bipolar disorder, schizophrenia, or other psychotic disorders, personality disorders, delirium, dementia and amnesic and other cognitive disorders, or are in a current agitated state.\n2. Have first-degree biological relatives (parents or full siblings) with past or present history of schizophrenia, bipolar disorder and any other psychosis.\n3. Meet DSM-5 criteria for panic disorder or seizure disorders.\n4. Meet DSM-5 criteria for dependence of any substance other than cannabis or tobacco in the past 6 months.\n5. Positive urine drug screen for substances tested with the exception of cannabis\n6. History of serotonergic psychedelic use in the past year and over 5 times of lifetime use (psilocybin, LSD, Ayahuasca, mescaline, DMT).\n7. Current treatment with psychotropic agents including stimulants, anti-psychotic agents, benzodiazepines and tri-cyclic anti-depressants. Concurrent treatment with Selective Serotonin Reuptake Inhibitors and Serotonin Noradrenalin Reuptake Inhibitors will be allowed, provided the dose has been stable for 4 weeks and remains stable during the study.\n8. History of cardiovascular diseases or uncontrolled hypertension that is not successfully treated or any other medical condition that might pose a risk to the participant in the opinion of the study physician.\n9. Are receiving concurrent psychotherapy for CUD.\n10. Are reasonably judged to present a serious suicide risk as determined by Columbia Suicide Severity Rating Scale or expressed homicide risk, who have enacted suicidal behaviors within 6 months prior to intake, or w ho are likely to require psychiatric hospitalization during the study.\n11. Participants of childbearing potential with a positive pregnancy test at screening or prior to dosing sessions, or are pregnant, breast feeding, and who are not using an acceptable means of birth control for the duration of the study.\n12. Are unable to fully understand the potential risks and benefits of the study and give informed consent.\n13. Are currently or planning on participating in other interventional clinical trials during this study.",{"count":84,"type":20},16,[56],"Cannabis is the most commonly used psychoactive substance in Canada (Lowry \\& Corsi, 2020). A sub-group of cannabis users develop a condition known as Cannabis Use Disorder (CUD), which is defined as a regular pattern of cannabis use that causes performance difficulty at work, school and relationships (Hasin et al., 2013). A review of current treatments available for CUD indicate the lack of a pharmacological and psychological treatment with high success rates, which highlights the importance of exploring potential psychosocial interventions for the treatment of CUD. Given the evidence of psilocybin's therapeutic potential in the treatment of substance use disorders (de Veen et al., 2017), we aim to conduct a study using psilocybin-assisted-psychotherapy in the treatment of CUD. The study aims to evaluate the feasibility, safety, tolerability and potential therapeutic effect of 2 doses \\[25 mg\\] of psilocybin administered as part of an 8-week Motivational Enhancement Therapy (MET) and supportive therapy. This trial will be the first to evaluate the potential treatment effects of psilocybin on symptoms of CUD.",[26,27],[29,89,30],"Psilocybin","2025-03-17",{"date":92,"type":36},"2025-03-19",{"date":94,"type":20},"2025-03",{"date":96,"type":20},"2026-06",{"name":42,"class":43}]